Compare AbbVie Inc (ABBV) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Wynn Resorts, Limited — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while Wynn Resorts, Limited trades at $97.82 (market cap $10.00B). The key difference: AbbVie Inc is far larger — about 45× Wynn Resorts, Limited's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | WYNN | |
|---|---|---|
Market Cap | $449.91B | $10.00B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $133.34 |
52-Week Low | $184.85 | $94.78 |
Enterprise Value | $513.38B | $20.36B |
Dividend Yield | 2.72% | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
Wynn Resorts (WYNN) trades at $96.35, up 0.46% on the day, with a bearish technical signal and recent earnings misses. Revenue reached $7.14B in 2025, but net income declined to $327M, reflecting margin pressure. Analyst consensus remains strongly bullish with a $136.22 price target, though high debt and competitive headwinds persist. The company announced Q2 2026 earnings for August 4, 2026, with investor focus on Macau and Las Vegas performance.
The stock presents a contrarian opportunity given analyst optimism amid technical weakness. Upside hinges on earnings recovery and debt management, but risks include geopolitical tensions in Macau and sustained margin compression. Current valuation at P/E 27.47 may limit near-term gains without profit improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
